Pulmonary Disease in Cystic Fibrosis

Kendig's Disorders of the Respiratory Tract in Children

Volumn , Issue , 2006, Pages 873-886

  Davis, Pamela B ^a,b  

^a STONY BROOK UNIVERSITY   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34247103783     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-3695-5.50065-1     Document Type: Chapter

References (62)

1. Boucher RC Regulation of airway surface liquid volume by human airway epithelia. Pflugers Arch 2003, 445(4):495-498.
2. Boucher RC An overview of the pathogenesis of cystic fibrosis lung disease. Adv Drug Deliv Rev 2002, 54(11):1359-1371.
3. Kunzelmann K CFTR. Interacting with everything?. News Physiol Sci 2001, 16:167-170.
4. Verkman AS, Song Y, Thiagarajah JR Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease. Am J Physiol Cell Physiol 2003, 284(1):C2-C15.
5. Steagall WK, Elmer HL, Brady KG, Kelley TJ Cystic fibrosis transmembrane conductance regulator-dependent regulation of epithelial inducible nitric oxide synthase expression. Am J Respir Cell Mol Biol 2000, 22(1):45-50.
6. Berger M Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good?. Clin Rev Allergy 1991, 9(1-2):119-142.
7. Berger M Lung inflammation early in cystic fibrosis: Bugs are indicted, but the defense is guilty. Am J Respir Crit Care Med 2002, 165(7):857-858.
8. Bedrossian CW, Greenberg SD, Singer DB, et al. The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups. Hum Pathol 1976, 7(2):195-204.
9. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. A randomized controlled trial. JAMA 2003, 290(13):1749-1756.
10. Vandamme P, Holmes B, Coenye T, et al. Burkholderia cenocepacia sp. nov.-a new twist to an old story. Res Microbiol 2003, 154(2):91-96.
11. Coenye T, LiPuma JJ Molecular epidemiology of Burkholderia species. Front Biosci 2003, 8:e55-e67.
12. Biddick R, Spilker T, Martin A, LiPuma JJ Evidence of transmission of Burkholderia cepacia, Burkholderia multivorans and Burkholderia dolosa among persons with cystic fibrosis. FEMS Microbiol Lett 2003, 228(1):57-62.
13. Lewin LO, Byard PJ, Davis PB Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients. J Clin Epidemiol 1990, 43(2):125-131.
14. Maiz-Carro L, Navas-Elorza E Nontuberculous mycobacterial pulmonary infection in patients with cystic fibrosis. Diagnosis and treatment. Am J Respir Med 2002, 1(2):107-117.
15. Wang EE, Prober CG, Manson B, et al. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med 1984, 311(26):1653-1658.
16. Wheeler WB, Williams M, Matthews WJ, Colten HR Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels. A 5-year longitudinal study. J Pediatr 1984, 104(5):695-699.
17. Muhlebach MS, Noah TL Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis. Am J Respir Crit Care Med 2002, 165(7):911-915.
18. Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995, 151(4):1075-1082.
19. Birrer P, McElvaney NG, Rudeberg A, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994, 150(1):207-213.
20. Chmiel JF, Davis PB State of the art: Why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection?. Respir Res 2003, 4(1):8.
21. Koscik RE, Kosorok MR, Farrell PM, et al. Wisconsin cystic fibrosis chest radiograph scoring system. Validation and standardization for application to longitudinal studies. Pediatr Pulmonol 2000, 29(6):457-467.
22. Demirkazik FB, Ariyurek OM, Ozcelik U, et al. High resolution CT in children with cystic fibrosis. Correlation with pulmonary functions and radiographic scores. Eur J Radiol 2001, 37(1):54-59.
23. Marchant JM, Masel JP, Dickinson FL, et al. Application of chest high-resolution computer tomography in young children with cystic fibrosis. Pediatr Pulmonol 2001, 31(1):24-29.
24. Ranganathan SC, Bush A, Dezateux C, et al. Relative ability of full and partial forced expiratory maneuvers to identify diminished airway function in infants with cystic fibrosis. Am J Respir Crit Care Med 2002, 166(10):1350-1357.
25. Konstan MW, Walenga RW, Hilliard KA, Hilliard JB Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis 1993, 148(4):896-901. Pt 1.
26. Ordonez CL, Henig NR, Mayer-Hamblett N, et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 2003, 168(12):1471-1475.
27. Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995, 152(6):2111-2118. Pt 1.
28. Noah TL, Black HR, Cheng PW, et al. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J Infect Dis 1997, 175(3):638-647.
29. Konstan MW, Hilliard KA, Norvell TM, Berger M Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994, 150(2):448-454.
30. Farrell PM, Li Z, Kosorok MR, et al. Longitudinal evaluation of bron-chopulmonary disease in children with cystic fibrosis. Pediatr Pulmonol 2003, 36(3):230-240.
31. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992, 326:1187-1191.
32. 1 may adversely affect overall survival. Chest 1999, 115(3):782-787.
33. Augarten A, Akons H, Aviram M, et al. Prediction of mortality and timing of referral for lung transplantation in cystic fibrosis patients. Pediatr Transplant 2001, 5(5):339-342.
34. Groman JD, Hefferon TW, Casals T, et al. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet 2004, 74(1):176-179.
35. Navarro J, Rainisio M, Harms HK, et al. Factors associated with poor pulmonary function. Cross-sectional analysis of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis. Eur Respir J 2001, 18(2):298-305.
36. Davis PB The gender gap in cystic fibrosis survival. J Gend Specif Med 1999, 2(2):47-51.
37. Demko CA, Byard PJ, Davis PB Gender differences in cystic fibrosis. Pseudomonas aeruginosa infection. J Clin Epidemiol 1995, 48(8):1041-1049.
38. Schechter MS, Shelton BJ, Margolis PA, Fitzsimmons SC The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med 2001, 163(6):1331-1337.
39. Drumm ML Modifier genes and variation in cystic fibrosis. Respir Res 2001, 2(3):125-128.
40. Konstan MW, Butler SM, Wohl ME, et al. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr 2003, 6:624-630.
41. Farrell PM, Kosorok MR, Laxova A, et al. Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. N Engl J Med 1997, 337(14):963-969.
42. Merelle ME, Schouten JP, Gerritsen J, Dankert-Roelse JE Influence of neonatal screening and centralized treatment on long-term clinical outcome and survival of CF patients. Eur Respir J 2001, 18(2):306-315.
43. Farrell PM, Li Z, Kosorok MR, et al. Bronchopulmonary disease in children with cystic fibrosis after early or delayed diagnosis. Am J Respir Crit Care Med 2003, 168(9):1100-1182.
44. Hoiby N Antibiotic therapy for chronic infection of Pseudomonas in the lung. Annu Rev Med 1993, 44:1-10.
45. Cheer SM, Waugh J, Noble S Inhaled tobramycin (TOBI). A review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs 2003, 63(22):2501-2520.
46. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990, 141(4):914-921. Pt 1.
47. Jones AP, Wallis CE Recombinant human deoxyribonuclease for cystic fibrosis. Cochrane Database Syst Rev 2003, 3:CD001127.
48. Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 1995, 126(4):515-523.
49. Konstan MW, Byard PJ, Hoppel CL, Davis PB Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995, 332(13):848-854.
50. Southern K, Barker P, Solis A Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2004, 2:CD002203.
51. Saiman L, Siegel J Infection control in cystic fibrosis. Clin Microbiol Rev 2004, 17(1):57-71.
52. Cantin AM Novel approaches to inflammation and infection in the cystic fibrosis lung. Pediatr Pulmonol 2001, (23):94-96.
53. Egan TM, Detterbeck FC, Mill MR, et al. Long term results of lung transplantation for cystic fibrosis. Eur J Cardiothorac Surg 2002, 22(4):602-609.
54. Davis PB, Drumm M, Konstan MW Cystic fibrosis. Am J Respir Crit Care Med 1996, 154(5):1229-1256.
55. Cystic Fibrosis Foundation: Patient Registry 2002 Annual Data Report to the Center Directors. Bethesda, Md: Cystic Fibrosis Foundation, 2003.
56. Flume PA Pneumothorax in cystic fibrosis. Chest 2003, 123(1):217-221.
57. Schidlow DV, Taussig LM, Knowles MR: Cystic Fibrosis Foundation consensus conference report on pulmonary complications of cystic fibrosis. Pediatr Pulmonol 1993;15(3):187-198.
58. Brinson GM, Noone PG, Mauro MA, et al. Bronchial artery embolization for the treatment of hemoptysis in patients with cystic fibrosis. Am J Respir Crit Care Med 1998, 157(6):1951-1958. Pt 1.
59. Stevens DA, Moss RB, Kurup VP, et al: and participants in the Cystic Fibrosis Foundation Consensus conference: Allergic bronchopulmonary Aspergillosis in cystic fibrosis-state of the art. Cystic Fibrosis Foundation Consensus conference. CID 2003;37(Suppl 3):S225-S264 .
60. Ledson MJ, Tran J, Walshaw MJ Prevalence and mechanisms of gastro-oesophageal reflux in adult cystic fibrosis patients. JR Soc Med 1998, 91(1):7-9.
61. Malfroot A, Dab I New insights on gastro-oesophageal reflux in cystic fibrosis by longitudinal follow-up. Arch Dis Child 1991, 66(11):1339-1345.
62. Heine RG, Button BM, Olinsky A, et al. Gastro-oesophageal reflux in infants under 6 months with cystic fibrosis. Arch Dis Child 1998, 78(1):44-48.